Nestlé Health Science joins €14.5m Enterome series-C

Alice Tchernookova
20 April 2016

Tweet
Facebook
LinkedIn
Google plus
Send to

French pharma company Enterome has raised €14.5m in a series-C round led by previous investors and joined by Nestlé Health Science and other new backers.

Previous investors include Seventure via its new Health for Life Capital fund, as well as Lundbeckfond Ventures. Omnes Capital, which was part of the company's series-B round, did not participate.

Nestlé Health Science, a Nestlé subsidiary focused on developing the role of nutritional therapy to impact on consumers' health, joined the round as a new strategic investor. Access to Nestlé's expertise in the field will help Enterome broaden its research, while the former will expand its microbiome portfolio ranging from diagnosis to therapeutics and nutritional therapies.

The funds will be used to help push Enterome's lead drug candidate EB 8018 into first clinical studies throughout 2016. The drug targets the treatment of inflammatory bowel diseases (IBD).

Enterome will also pursue research into IBD and other microbiome-related diseases, and will look to finance therapeutic programmes in immuno-oncology.

Previous funding
Enterome has raised a total of €32m from various venture capital investors, with previous series-A and -B rounds involving Seventure, Lundbeckfond and Omnes, as well as strategic investors such as Shire and the French National Institute for Agricultural Research (INRA).

Company
Enterome is a Paris-based medicine company developing drugs for chronic medical conditions related to bacterial composition abnormalities.

It develops pharmaceuticals and diagnostics to support personalised therapies in microbiome-related diseases such as IBD, cancer and metabolic diseases.

Enterome has partnerships with pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation, Janssen Biotech and the Mayo Clinic and Geisinger hospitals for metabolic disorders.

The company was established in 2012 to develop discoveries made by INRA in the field.

People
Nestlé Health Science – Greg Behar (CEO).